Congratulations to the new CEO Nicola CaronzoloSINTETICA CELEBRATES ONE HUNDRED YEARS IN BUSINESS AND LOOKS TO THE FUTURE
12.11.2021
MENDRISIO, Switzerland, November 12, 2021 – Today Sintetica SA is celebrating its one hundredth anniversary with events that project the company into the future.
Christian Vitta, State Councilor and Director of the Canton's Department of Finance and Economy, and Raffaele De Rosa, Director of the Department of Health and Social Affairs and State Councilor, will be present. Co-director of the Department of Physiology and Cellular Biophysics at Columbia University Prof. Filippo Mancia and Prof. Dr. med. Alain Borgeat, Director of the Department of Anesthesiology at Balgrist Orthopedic University Hospital in Zurich, will join an esteemed group of international guests for a scientific symposium titled "The Molecules of Life". Together with Fondazione AGIRE and Università della Svizzera Italiana, Sintetica will also present the first-ever Sintetica Innovation Award to a winning startup in a competition that was created to recognize promising and innovative Swiss start-ups in the fields of healthcare and life sciences. The celebrations mark an important step for Sintetica. Unveiling an updated mission statement, Sintetica will reaffirm its commitment to improving therapies based on clinicians' insights to improve patients' lives. This commitment continues in the direction of caring for people's well-being, as well as maintaining strong connections with the Swiss territory and hospitals. A new visual identity, which will be unveiled as part of the celebrations, will express this commitment visually in form of a refreshed logo and corporate design, which build on the company's strong historical roots to project Sintetica into the future. The new look and feel will be implemented gradually across all touchpoints in a phased approach. "I am excited and honored to welcome our distinguished guests to today's Century Celebration, and equally pleased and proud be joined by the winners and finalists of our first-ever Innovation Award at this wonderful event," said Dr. Miro Venturi, CEO of Sintetica SA. “With our refreshed visual identity, we celebrate our history, expand our horizons and prepare Sintetica for another century of improving patients’ lives." Continue reading ->
<- Close
Sintetica Appoints Chief Commercial Officer
16/08/2021
Jamie Sparrow appointed Chief Commercial Officer
We are very pleased to announce the appointment of Jamie Sparrow to the newly created position as Chief Commercial Officer, effective August 16, 2021. Reporting to CEO Dr. Miro Venturi, Mr. Sparrow will be responsible for global commercial strategy and execution in this newly created position.
About Mr. Sparrow
A highly professional and entrepreneurial executive, Mr. Sparrow joins us from Glenmark, a global innovative pharmaceutical company based in Mumbai, where he most recently led commercial strategy and operations as Senior Vice President and Head of Europe. In a career spanning more than 30 years, Mr. Sparrow has held senior leadership roles with Arrow Generics, Watson Pharmaceuticals, Actavis and Mylan. Mr. Sparrow brings several key competencies to Sintetica, including business development, sales and marketing and strong general management, acquired in international and regional roles. He has a track record of delivering on demanding business targets, including full country/regional profit and loss responsibilities, focusing on establishing a “win-win” approach with colleagues, customers, suppliers and other key stakeholders. About Sintetica As we explore ways to bring better products to patients and HCPs faster, Mr. Sparrow’s broad commercial expertise will play a key role in evolving the business strategically as well as identifying and quickly seizing market opportunities as they emerge. Looking back at 100 years of history and with roots in Switzerland, we are embarking on a new phase of accelerated international growth. As a leading supplier of analgesics, local anesthetics and sterile injectable solutions in ampoules, vials and IV bags for hospitals, we develop and deliver products that are differentiated from traditional generic medicines and increase patient safety as well as convenience for the HCPs that administer these products. Our products are sold through sales subsidiaries in selected European markets and through partnerships with leading distributors around the world.
We welcome Mr. Sparrow to Sintetica and wish him great success!
Continue reading ->
<- Close
Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica
27/07/2021
New Drug Application Expected to Be Filed in Late 2021
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions, to acquire the marketing and supply rights in the U.S. and Canada for AMP‑100, a patented ophthalmic surgical drug candidate. When approved, AMP-100 will provide ocular surface anesthesia during ophthalmic interventions such as cataract surgery and intravitreal injections, which are estimated to total over 10 million procedures annually in the U.S.(1)
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions, to acquire the marketing and supply rights in the U.S. and Canada for AMP‑100, a patented ophthalmic surgical drug candidate. When approved, AMP-100 will provide ocular surface anesthesia during ophthalmic interventions such as cataract surgery and intravitreal injections, which are estimated to total over 10 million procedures annually in the U.S.(1)
AMP-100 is a patented, innovative ocular surface anesthetic drug candidate, with safety and efficacy supported by a robust pre-clinical and clinical program, including a recently completed Phase 3 study that successfully compared the efficacy and tolerability of AMP-100 to current standards of care. Sintetica intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in late 2021. When approved, the active ingredient used in AMP-100 will be the first approved use of this active ingredient in the U.S. ophthalmic market. Commenting on the acquisition, Mark L. Baum, CEO of Harrow Health, said, “This transaction reflects Harrow Health’s commitment to continued growth by adding new high-value products to our portfolio. The acquisition of rights to market and sell AMP-100 in the U.S. and Canada will further fortify our greatest commercial strength – providing thousands of U.S. eyecare professionals and their patients with novel ophthalmic surgical products. When approved, we expect to fully leverage our wholly owned, efficient, scalable, and tech-enabled ImprimisRx ophthalmic-focused commercial and distribution platform to market AMP-100 to our ‘front-of-the-eye-focused’ customer base, such as cataract and refractive surgeons. In addition, we intend to invest in expanding our commercial footprint to include retina-focused surgeons to fully leverage the market potential of AMP-100.” “We have a sound business strategy for commercializing our promising and innovative products in countries around the world,” added Miro Venturi, Corporate CEO for Sintetica, S.A. “We are convinced that Harrow Health, with its knowledge and expertise in ophthalmology and commitment to providing high‑quality medications, is the optimal choice for Sintetica to partner with to bring AMP‑100 to the U.S. market.” Under the terms of the agreement, Sintetica will be responsible for regulatory filings for the product in the U.S. The agreement provides for upfront and milestone payments to Sintetica as well as per unit royalties on sales of AMP-100, when successfully commercialized. Harrow Health will have marketing rights for the U.S. and Canada, while Sintetica will retain the marketing rights in other countries. B. Riley Securities acted as financial advisors to Harrow Health for the transaction. About Sintetica Based in Mendrisio, Switzerland, Sintetica is a growing privately held international pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions in ampoules, vials and IV bags for hospitals. Sintetica develops medicines in concentrated and premixed formulations, which enables healthcare practitioners to administer these products without manipulation and dilution, increasing patient safety and improving convenience for patients and HCPs. Sintetica runs sales subsidiaries in selected European markets and partners with leading distributors around the world. In 2020, Sintetica employed 277 employees and produced 52.9 million products, with revenues of close to CHF 90 million. For more information about Sintetica, please visit the corporate website, sintetica.com. About Harrow Health Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include the impact of the COVID-19 pandemic and any future health epidemics on our financial condition, liquidity and results of operations; our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; market acceptance of the Company’s formulations and challenges related to the marketing of the Company’s formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow Health’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Contacts: For Sintetica: Daniel Braxton Head Branding & Communications dbraxton@sintetica.com +41 79 514 94 97 For Harrow: Investors Jamie Webb, Director of Communications and IR jwebb@harrowinc.com 615-733-4737 References: (1) Market Scope 2019, IOL Market Report, April 2019, and Ophthalmologica, 2018 Update on Intravitreal Injections, accessed 7/27/21 Continue reading ->
<- Close
We are delighted to announce that Miro Venturi is our new Corporate CEO. Welcome aboard Miro!Miro has received a combined humanistic and scientific education by first attending the Liceo Linguistico in Faenza and later studying chemistry and biology at the University of Bologna, where he received his first degree in Biology and Biochemistry. After that, Miro earned his Doctorate (PhD) in Biophysics at the Max-Planck Institute of Frankfurt/Main, Germany, (in the Team of Nobel laureate Prof. Dr. Hartmut Michel) and later a postdoctoral specialization in Molecular Medicine at the National Institutes of Health in Bethesda, Maryland, under the US Government sponsorship. His scientific work lead to several patents and has been published in more than 60 peer-reviewed international articles and internationally cited across the academic and industrial communities. Miro joined the pharmaceutical industry in 2000, driven by the desire to apply science for the benefits of patients: he has built translational sciences and patients’ focused drug development organizations across a range of therapeutic areas, always with an emphasis in helping to globally scale biomarker-driven drug development, and realize the promise of precision medicine and personalized therapies. This work has helped Roche Pharmaceuticals to significantly streamline, accelerate and improve drug development and pipeline activity, leading to the successful market launch of numerous blockbuster drugs in recent years. At Roche, Miro has been Global Project Leader, then Global Head of Oncology Personalized Healthcare to later becoming a senior executive within the Roche Divisional Strategy & Business Development organization, where his Team was responsible for the assessment of licensing, mergers and acquisition opportunities and deals supporting the precision medicine strategy of the company worldwide. Miro and his Team’s activities have also been instrumental for the Roche Diagnostics Division to embrace the digital revolution and launch products (such as the NAVIFy platform and associated SaaS products) to expand its customer base to physicians and execute upon a new diagnostic value-based business model. Miro’s most recent role within the Roche Group has been as Chief Business Officer and Member of the Executive Committee for Foundation Medicine, a company leader in the field of next generation data-driven diagnostics for cancer patients. Miro is a native Italian and speaks English, German and French.
Continue reading ->
<- Close
toYOU, the person at the centre
Signed agreements between employees and the company which enable employees to give life and substance to essential life projects: in the areas of training, family care and socio-cultural paths. It is with pride that Sintetica, the oldest pharmaceutical company in Canton of Ticino, presents toYOU, its most recent and innovative action in the context of the human centric organisation.
Sintetica believes that important life projects undertaken by its employees should be supported by facilitating their implementation as far as possible. From this vision, which rewrites the concept of benefits, the great construction site "toYOU: the project pacts in Synthetica" was born.
These three areas were as a holistic declination of the "manocentric" vision, an entrepreneurial and humanistic philosophy that constitutes the profound essence of this highly innovative company. Continue reading ->
<- Close
Global Pharmaceutical CEO of the year 2020
From the United States comes an important recognition for Sintetica. The magazine Corporate America Today has awarded our CEO Augusto Mitidieri as Global Pharmaceutical CEO of the year 2020.
The Humancentric organizational model and its ability to foster innovation have impressed the panel of experts. It has also been underlined how Sintetica met the swiss and the international demand of its Intensive Care Unit‘s drugs at global level during this CV19 emergency. Once again, Sintetica nds success at international level for its true excellence: its people.
Congratulations to our CEO, heartfelt and a ectionate. To all of you a big and sincere thanks for what you do every day. Continue reading ->
<- Close
Congratulations Augusto Mitidieri, Corporate CEO
Corporate American Today awards Augusto Mitidieri, Corporate CEO, Global Pharmaceutical CEO of the Year 2020
Augusto Mitidieri - Most Influential CEO Europe 2019 for Humancentric Driven Innovation -An internationally recognised, concrete example of scientific innovation and innovative corporate philosophy. The path undertaken by Sintetica (the oldest pharmaceutical company in Ticino), guided by its CEO Augusto Mitidieri, is not only littered with success on the global markets but is also making a name for itself with its innovative strength and ability. It is no coincidence that “Leadership by Innovation” is one of its distinguishing features.
Recently a new award, presented by CV Magazine to Augusto Mitidieri as the “Most Influential CEO Europe 2019 for Humancentric Driven Innovation”, has further confirmed the high quality of this story of courage and success.
In the interview conducted by the magazine (www.cv-magazine.com/2019-humancentric-driven-innovation), Sintetica's CEO focuses on some of the cornerstones of this revolution in growth and development methods, of course, but also on the development of a different kind of corporate philosophy. This award is a source of great satisfaction for this modern company, specialised in the production of top quality drugs for pain management and local anaesthesia. Continue reading ->
<- Close
Le Fonti Awards 2019
13/11/2019
Augusto Mitidieri - CEO of the Year for Sustainability in pharma industry
An innovative strategy and corporate philosophy pursued with perseverance and determination have earned Sintetica’s CEO, Augusto Mitidieri, an important new award. Le Fonti Awards have, in fact, named him "CEO of the Year for Sustainability in pharma industry" for the third year running.
Augusto Mitidieri was presented with the coveted award during a ceremony held in Milan. The official motivation behind the award, also released publically, is as follows: " For confirming himself for the third year running as the most far-sighted CEO in the pharmaceutical sector in terms of sustainability: his innovative approach to care, human resource development and a focus on the environment mean he is the one setting the benchmark at international level.
 Continue reading ->
<- Close
Business Worldwide CEO Awards 2019
17/09/2019
Augusto Mitidieri is the "Most Innovative Pharmaceutical CEO – Europe”
A new prestigious award has been assigned to the CEO of Sintetica Augusto Mitidieri, named “Most Innovative Pharmaceutical CEO – Europe” for 2019 by Business Worldwide Magazine (BWM).
Augusto Mitidieri, as the BWM press release reports, won the title outright “impressing the judges with his collaborative management strategy”.
The goal of the Business Worldwide CEO Awards 2019 is to identify and celebrate exceptional leaders from all parts of the world in various sectors. Unlike other titles, generally focused on the company structures, the focus of the Business Worldwide CEO Awards is on the individual, their leadership abilities and the unique qualities that set them apart from the others. By illustrating their talent and management skills, the intention is to encourage and motivate other business leaders to achieve similar goals. Commenting on the concept of the human-centric vision on which he decided to mould Sintetica, Augusto Mitidieri told BWM: “Passion is the real driving force behind Sintetica. And it is important for our people to be aware that they can make a di erence and help change things for the better, knowing that every action has an impact on society. We encourage people to smile. And a real smile is contagious. It identi es Sintetica and represents the real essence of the concept of a great place to work”. Continue reading ->
<- Close
05/09/2019
Sintetica from Westminster to the World
Sintetica has been chosen to feature in a commemorative album marking the 70th anniversary of the Commonwealth. "I would like to share with you an honour bestowed upon our company because of the unique human-centred way Sintetica is run, which is seen as a global model for sustainability and is the foundation of our future as a successful business.
Sintetica is one of only two pharmaceutical companies, to have been chosen to feature in a commemorative album marking the 70th anniversary of the Commonwealth. It is one of the most ambitious, authoritative and well-researched academic projects in British history.
I, personally, was interviewed by His Royal Highness Prince Charles’ biographer and royal correspondent, Robert Jobson, who asked me about the work of Sintetica and why respect, innovation and diversity are so important.
HRH Prince Charles will become head of the Commonwealth when his mother, Her Majesty, Queen Elizabeth II stands down. Prince Charles has long been a supporter of sustainability and the environment. He worked with Cambridge University to set up the Business and Sustainability Programme for business leaders and senior executives who need to make the right long-term decisions to ensure their organizations grow sustainably and profitably; which is why Prince Charles worked with the History of Parliament Trust to select the organizations chosen to be a part of this significant project in British history.
The commemorative album “The Commonwealth at 70: From Westminster to the World” includes photographs, stories and thought-provoking debate on all aspects of the states that make up the Commonwealth. It brings together best practice and offers an insight into the major Commonwealth institutions, organizations and initiatives. It shows how countries can work together for the common interests of its peoples. Business can learn from this understanding and co-operation.
I am proud of the work we do and thrilled to have received such a recognition at Westminster Abbey in London, which has one thousand years of heritage and seen many royal occasions.
Thank you for your precious support holding Sintetica up to the world as a model for success and sustainability." Continue reading ->
<- Close
26/04/2019
Augusto Mitidieri Corporate CEO of Sintetica Awarded Best Manager of the YearAugusto Mitidieri, CEO, has been awarded Best Manager of the Year for high achievements and professionalism in the company management. Awarded by The Socrates Committee of Oxford this award recognises exceptional human-centric leadership and the global success of Sintetica. This award was presented at the Socrates Award Ceremony of the Achievements Forum 2019, Institute of Directors, London.
Additionally, the Europe Business Assembly (EBA) Corporation of Social Partnership awarded Sintetica SA, Switzerland, Best Enterprise Award. “Recognition of the exceptional global leadership of our CEO, Augusto Mitidieri, not only distinguishes an inspirational leader, it provides all of Sintetica with a huge feel good factor. Sintetica is a great place to work and feeling good about the work that we all do is in the heart of all of us.”Speaking from London, Darren Fergus, Managing Director Continue reading ->
<- Close
Most Influential CEO of the Year 2018 – Europe
The CEO of Sintetica Mendrisio has been presented with this prestigious award from CV-Magazine. “Most Influential CEO of the Year 2018 – Europe”.
This is the new and prestigious award which Corporate Vision Magazine has presented to Augusto Mitidieri, CEO of Sintetica, the oldest pharmaceutical company in the Canton of Ticino.
In presenting this award, which marks an additional milestone in the international recognition of the corporate strategy which Sintetica has been following under the leadership of its CEO, CV-Magazine focuses in particular on the elements that make up the “human-centric” philosophy which Mitidieri has brought to the operative and functional heart of the company.
To this end, the conclusion to the article/interview which CV-Magazine published in its latest issue is of note (www.cv-magazine.com/issues/issue-3-2019/6/): “Augusto and the team at Sintetica will continue to deliver their exceptional services which has seen them take great strides within the industry, leading the way for others to follow. Additionally, Augusto will continue to direct his team towards success with his award-winning leadership skills, especially following his recent recognition in Corporate Vision’s 2018 Leadership Elite Awards where he was righteously awarded to accolade Most Influential CEO of the Year 2018 – Europe”. Continue reading ->
<- Close
CV Magazine - Small Business Awards 2018
EUROPEAN CEO AWARDS 2018
THE CEO OF SINTETICA
|
